At The Kids, commercialisation is not merely a transactional process; it is a strategic enabler and a catalyst for transformative impact.
By translating innovative discoveries and products of our research into tangible and commercially sustainable solutions, it empowers our researchers to positively influence the health outcomes of the youngest and most vulnerable members of society.
Whether it's novel therapies, educational materials, child-focused applications or software solutions, diagnostic tools, or medical devices designed for children, successful commercialisation ensures these advancements reach young patients, improving paediatric healthcare.
Beyond our researchers' direct impact, the financial returns from commercialisation will enable program sustainability, continued funding of ongoing research, attracting top talent, and sustaining our state-of-the-art facilities. Ultimately, commercialisation amplifies the institute's ability to create lasting positive change in the health and well-being of children.
Commercial opportunities
The Kids is seeking partners to develop and commercialise our technology opportunities. We are looking for investment, collaboration and licensing partners for our technologies. Below are the list of opportunities available for partnering. Please contact us at commercialisation@thekids.org.au if you wish to discuss any of these opportunities, or any other areas of commercial interest.
| Therapeutic | ||||||
| Technology name | Disease | Modality | Mechanism of Action | Development stage | Partnering available | |
|---|---|---|---|---|---|---|
| Immunotherapy Gel | Oncology Solid Tumors | dsRNA | TLR 3 agonist | Pre-clinical | Yes | |
| Epithelial Cell Repair | Asthma IBD IPF | Small molecule | Undisclosed | Hit discovery | Yes | |
| SpritzOM | Otitis Media | Live biotherapeutic | Undisclosed | Pre-clinical | Yes | |
| Taste Masking Product | Pain/anxiety relief | Small molecule reformulation | NA | Regulatory | Yes | |
| Bacteriophage Therapy | AMR | Live biotherapeutic | Phage | Pre-clinical | Yes | |
| Diagnostic Tools | ||||
| Technology name | Disease | Technology | Development stage | Partnering available |
|---|---|---|---|---|
| VUS Diagnosis Pipeline for Rare Genetic Disease | Genetic disease gene mutation | Next Generation Sequencing | In development | Yes |
| PoC Antibiotic Resistance Test | Strep A | Isothermal DNA Amplification | In development | Yes |
| Social and behavioural sciences | |
| Technology name | Description |
|---|---|
| QI-disability | QI-disability was developed to specifically assess the quality of life of children and adolescents with intellectual disability. It is available for licensing as an outcome measure for clinical trials. Find out more. |
| Friendly Schools | Friendly Schools helps build critical social and emotional skills, create positive, safe and supportive learning environments, and significantly reduce bullying in both primary and secondary schools. Find out more. |
| CUES Autism Group Therapy |
Group therapy for parents or other primary caregivers that helps families understand how to support and mange their child’s challenges with uncertainty in everyday environments. |
| Inklings |
Inklings is a program for babies aged 6-18 months who are showing early differences in their social interaction and communication development. Find out more. |
| Digital health and software solutions | |||
| Technology name | Description | Development stage | Partnering available |
|---|---|---|---|
| Virtual WA | Modelling software that uses big data to map out physical and social geography. | Preliminary validation | Yes |
| AI Platform for Articulating Methods and Reason | Software that accurately, equitably, and automatically interprets highly complex and multi-dimensional data. | Proof of feasibility | Yes |
| Act1ve app Diabetes type 1 | App that contains exercise guidelines and tailored advice specifically for young people living with T1D. |
Prototype |
Yes |
